ArticleRare tumors2021

Phase II study of dacarbazine given with modern prophylactic anti-emetics and growth factor support to patients with metastatic, resistant soft tissue, and bone sarcoma.

Brian A Van Tine et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.